HK Stock MarketDetailed Quotes

01548 GENSCRIPT BIO

Watchlist

12.800
-0.500-3.76%

Market Closed Aug 14 16:08 CST

27.24BMarket Cap-19722P/E (TTM)

GENSCRIPT BIO Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

(FY)Dec 31, 2020

(Q6)Jun 30, 2020

(FY)Dec 31, 2019

Turnover

43.46%561.37M

34.17%839.53M

26.40%391.31M

27.67%625.7M

34.86%309.59M

25.39%490.1M

37.97%229.57M

42.98%390.85M

36.53%166.39M

18.33%273.35M

Operating income

43.46%561.37M

34.17%839.53M

26.40%391.31M

27.67%625.7M

34.86%309.59M

25.39%490.1M

37.97%229.57M

42.98%390.85M

36.53%166.39M

18.33%273.35M

Cost of sales

-17.63%-254.39M

-33.69%-429.98M

-53.28%-216.26M

-54.94%-321.62M

-55.13%-141.09M

-53.82%-207.58M

-56.21%-90.95M

-45.01%-134.95M

-35.46%-58.22M

-28.40%-93.06M

Operating expenses

-17.63%-254.39M

-33.69%-429.98M

-53.28%-216.26M

-54.94%-321.62M

-55.13%-141.09M

-53.82%-207.58M

-56.21%-90.95M

-45.01%-134.95M

-35.46%-58.22M

-28.40%-93.06M

Gross profit

75.37%306.99M

34.68%409.55M

3.89%175.05M

7.63%304.08M

21.55%168.5M

10.40%282.52M

28.15%138.62M

41.93%255.89M

37.10%108.17M

13.72%180.29M

Selling expenses

-19.57%-97.34M

-3.53%-174.3M

6.37%-81.4M

-0.23%-168.35M

-49.21%-86.94M

-56.48%-167.97M

-41.92%-58.27M

-52.56%-107.34M

-32.62%-41.06M

-81.47%-70.36M

Administrative expenses

-12.82%-120.17M

-16.98%-213.44M

-33.73%-106.52M

-35.65%-182.46M

-41.44%-79.65M

-48.89%-134.51M

-54.85%-56.31M

-63.50%-90.34M

-38.98%-36.37M

-36.16%-55.26M

Research and development expenses

-14.01%-236.38M

-10.95%-432.83M

-16.74%-207.33M

-8.84%-390.1M

-1.41%-177.61M

-36.07%-358.4M

-51.69%-175.13M

-41.60%-263.4M

-83.73%-115.45M

-151.12%-186.02M

Revaluation surplus

-226.82%-113.51M

131.54%43.46M

24.21%-34.73M

113.46%18.77M

-2,764.00%-45.82M

-74.32%-139.43M

98.00%-1.6M

---79.98M

----

-Changes in the fair value of other assets

-226.82%-113.51M

131.54%43.46M

24.21%-34.73M

113.46%18.77M

-2,764.00%-45.82M

-74.32%-139.43M

98.00%-1.6M

---79.98M

----

Impairment and provision

-1,646.64%-41.34M

-30.15%-16.44M

-54.20%-2.37M

---12.63M

-24.70%-1.54M

----

---1.23M

----

-Other impairment is provision

-1,646.64%-41.34M

-30.15%-16.44M

-54.20%-2.37M

---12.63M

-24.70%-1.54M

----

---1.23M

----

Operating interest expense

----

---3.3M

56.22%-2.38M

----

-595.52%-5.43M

-1,065.37%-4.51M

---781K

Special items of operating profit

339.66%110.4M

393.55%60.52M

835.07%25.11M

189.29%12.26M

-170.55%-3.42M

-54.41%4.24M

-56.10%4.84M

-54.86%9.3M

99.46%11.03M

9.44%20.6M

Operating profit

17.58%-191.36M

22.69%-323.47M

-1.05%-232.19M

18.90%-418.42M

-54.13%-229.78M

-83.40%-515.93M

5.74%-149.08M

-152.22%-281.31M

-340.32%-158.17M

-585.91%-111.53M

Financing cost

-14.15%-14.23M

-107.33%-27.51M

---12.46M

---13.27M

----

---1.14M

----

Share of profits of associates

----

-94.48%-599K

-125.90%-314K

-53.23%-308K

Special items of earning before tax

----

-20,614.29%-1.44M

----

100.38%7K

177.46%433K

---1.85M

Earning before tax

15.97%-205.59M

18.70%-350.98M

-6.47%-244.65M

16.56%-431.69M

-52.96%-229.78M

-83.53%-517.36M

4.95%-150.22M

-147.95%-281.9M

-331.60%-158.05M

-600.84%-113.69M

Tax

-809.69%-10.04M

-211.37%-4.14M

71.05%-1.1M

485.79%3.72M

35.65%-3.81M

-302.10%-964K

-140.66%-5.93M

112.47%477K

-174.97%-2.46M

-97.11%-3.83M

After-tax profit from continuing operations

12.26%-215.63M

17.02%-355.12M

-5.21%-245.76M

17.43%-427.97M

-49.59%-233.59M

-84.18%-518.33M

2.72%-156.15M

-139.48%-281.42M

-381.50%-160.51M

-666.10%-117.52M

Earning after tax

12.26%-215.63M

17.02%-355.12M

-5.21%-245.76M

17.43%-427.97M

-49.59%-233.59M

-84.18%-518.33M

2.72%-156.15M

-139.48%-281.42M

-381.50%-160.51M

-666.10%-117.52M

Minority profit

73.38%-40.52M

-29.10%-259.64M

-55.15%-152.18M

-26.00%-201.12M

-50.83%-98.08M

-108.71%-159.62M

-37.14%-65.03M

-271.18%-76.48M

-691.73%-47.42M

-4,408.53%-20.6M

Profit attributable to shareholders

-87.13%-175.12M

57.91%-95.48M

30.94%-93.58M

36.76%-226.85M

-48.71%-135.51M

-75.03%-358.71M

19.43%-91.12M

-111.48%-204.95M

-313.56%-113.09M

-556.79%-96.91M

Basic earnings per share

-86.26%-0.0827

58.13%-0.0453

31.48%-0.0444

38.77%-0.1082

-40.56%-0.0648

-63.91%-0.1767

23.29%-0.0461

-106.12%-0.1078

-306.08%-0.0601

-543.22%-0.0523

Diluted earnings per share

-86.26%-0.0827

58.13%-0.0453

31.48%-0.0444

38.77%-0.1082

-40.56%-0.0648

-63.91%-0.1767

23.29%-0.0461

-106.12%-0.1078

-306.08%-0.0601

-554.78%-0.0523

Currency Unit

USD

Accounting Standards

HKAS

Audit Opinions

Unqualified Opinion

Auditor

Ernst & Young

	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021	(FY)Dec 31, 2020	(Q6)Jun 30, 2020	(FY)Dec 31, 2019
Turnover	43.46%561.37M	34.17%839.53M	26.40%391.31M	27.67%625.7M	34.86%309.59M	25.39%490.1M	37.97%229.57M	42.98%390.85M	36.53%166.39M	18.33%273.35M
Operating income	43.46%561.37M	34.17%839.53M	26.40%391.31M	27.67%625.7M	34.86%309.59M	25.39%490.1M	37.97%229.57M	42.98%390.85M	36.53%166.39M	18.33%273.35M
Cost of sales	-17.63%-254.39M	-33.69%-429.98M	-53.28%-216.26M	-54.94%-321.62M	-55.13%-141.09M	-53.82%-207.58M	-56.21%-90.95M	-45.01%-134.95M	-35.46%-58.22M	-28.40%-93.06M
Operating expenses	-17.63%-254.39M	-33.69%-429.98M	-53.28%-216.26M	-54.94%-321.62M	-55.13%-141.09M	-53.82%-207.58M	-56.21%-90.95M	-45.01%-134.95M	-35.46%-58.22M	-28.40%-93.06M
Gross profit	75.37%306.99M	34.68%409.55M	3.89%175.05M	7.63%304.08M	21.55%168.5M	10.40%282.52M	28.15%138.62M	41.93%255.89M	37.10%108.17M	13.72%180.29M
Selling expenses	-19.57%-97.34M	-3.53%-174.3M	6.37%-81.4M	-0.23%-168.35M	-49.21%-86.94M	-56.48%-167.97M	-41.92%-58.27M	-52.56%-107.34M	-32.62%-41.06M	-81.47%-70.36M
Administrative expenses	-12.82%-120.17M	-16.98%-213.44M	-33.73%-106.52M	-35.65%-182.46M	-41.44%-79.65M	-48.89%-134.51M	-54.85%-56.31M	-63.50%-90.34M	-38.98%-36.37M	-36.16%-55.26M
Research and development expenses	-14.01%-236.38M	-10.95%-432.83M	-16.74%-207.33M	-8.84%-390.1M	-1.41%-177.61M	-36.07%-358.4M	-51.69%-175.13M	-41.60%-263.4M	-83.73%-115.45M	-151.12%-186.02M
Revaluation surplus	-226.82%-113.51M	131.54%43.46M	24.21%-34.73M	113.46%18.77M	-2,764.00%-45.82M	-74.32%-139.43M	98.00%-1.6M	---79.98M	---79.98M	----
-Changes in the fair value of other assets	-226.82%-113.51M	131.54%43.46M	24.21%-34.73M	113.46%18.77M	-2,764.00%-45.82M	-74.32%-139.43M	98.00%-1.6M	---79.98M	---79.98M	----
Impairment and provision	-1,646.64%-41.34M	-30.15%-16.44M	-54.20%-2.37M	---12.63M	-24.70%-1.54M	----	---1.23M	----	----	----
-Other impairment is provision	-1,646.64%-41.34M	-30.15%-16.44M	-54.20%-2.37M	---12.63M	-24.70%-1.54M	----	---1.23M	----	----	----
Operating interest expense	----	----	----	----	---3.3M	56.22%-2.38M	----	-595.52%-5.43M	-1,065.37%-4.51M	---781K
Special items of operating profit	339.66%110.4M	393.55%60.52M	835.07%25.11M	189.29%12.26M	-170.55%-3.42M	-54.41%4.24M	-56.10%4.84M	-54.86%9.3M	99.46%11.03M	9.44%20.6M
Operating profit	17.58%-191.36M	22.69%-323.47M	-1.05%-232.19M	18.90%-418.42M	-54.13%-229.78M	-83.40%-515.93M	5.74%-149.08M	-152.22%-281.31M	-340.32%-158.17M	-585.91%-111.53M
Financing cost	-14.15%-14.23M	-107.33%-27.51M	---12.46M	---13.27M	----	----	---1.14M	----	----	----
Share of profits of associates	----	----	----	----	----	----	----	-94.48%-599K	-125.90%-314K	-53.23%-308K
Special items of earning before tax	----	----	----	----	----	-20,614.29%-1.44M	----	100.38%7K	177.46%433K	---1.85M
Earning before tax	15.97%-205.59M	18.70%-350.98M	-6.47%-244.65M	16.56%-431.69M	-52.96%-229.78M	-83.53%-517.36M	4.95%-150.22M	-147.95%-281.9M	-331.60%-158.05M	-600.84%-113.69M
Tax	-809.69%-10.04M	-211.37%-4.14M	71.05%-1.1M	485.79%3.72M	35.65%-3.81M	-302.10%-964K	-140.66%-5.93M	112.47%477K	-174.97%-2.46M	-97.11%-3.83M
After-tax profit from continuing operations	12.26%-215.63M	17.02%-355.12M	-5.21%-245.76M	17.43%-427.97M	-49.59%-233.59M	-84.18%-518.33M	2.72%-156.15M	-139.48%-281.42M	-381.50%-160.51M	-666.10%-117.52M
Earning after tax	12.26%-215.63M	17.02%-355.12M	-5.21%-245.76M	17.43%-427.97M	-49.59%-233.59M	-84.18%-518.33M	2.72%-156.15M	-139.48%-281.42M	-381.50%-160.51M	-666.10%-117.52M
Minority profit	73.38%-40.52M	-29.10%-259.64M	-55.15%-152.18M	-26.00%-201.12M	-50.83%-98.08M	-108.71%-159.62M	-37.14%-65.03M	-271.18%-76.48M	-691.73%-47.42M	-4,408.53%-20.6M
Profit attributable to shareholders	-87.13%-175.12M	57.91%-95.48M	30.94%-93.58M	36.76%-226.85M	-48.71%-135.51M	-75.03%-358.71M	19.43%-91.12M	-111.48%-204.95M	-313.56%-113.09M	-556.79%-96.91M
Basic earnings per share	-86.26%-0.0827	58.13%-0.0453	31.48%-0.0444	38.77%-0.1082	-40.56%-0.0648	-63.91%-0.1767	23.29%-0.0461	-106.12%-0.1078	-306.08%-0.0601	-543.22%-0.0523
Diluted earnings per share	-86.26%-0.0827	58.13%-0.0453	31.48%-0.0444	38.77%-0.1082	-40.56%-0.0648	-63.91%-0.1767	23.29%-0.0461	-106.12%-0.1078	-306.08%-0.0601	-554.78%-0.0523
Currency Unit	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Accounting Standards	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS
Audit Opinions	--	Unqualified Opinion	--	Unqualified Opinion	--	--	--	--	--	Unqualified Opinion
Auditor	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

01548 GENSCRIPT BIO

GENSCRIPT BIO Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Analysis

Analyst Rating

Price Target